Befovacimab

贝弗西单抗

Report date: 2024/02/21 12:27:36

Base Information

Drug NameBefovacimab
Drug Alias NameAnti-TFPI antibodyBAY-109BAY-1093884
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionAnti-TFPI
TargetsTissue factor pathway inhibitor
Therapy Area/IndicationsHemophilia BHemophilia A
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBulgariaUkraineTaiwan +[14] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMorphosys AgBayer AG
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBayer AG
Active IndicationsN/A
Inactive IndicationsHemophilia BHemophilia A

Other Information

ATC CodeN/A
Related LinksN/A